Call Us: 1.800.873.5297


Actos (Pioglitazone) and Bladder Cancer

Actos is a prescription medication manufactured by Takeda which is prescribed to control glucose (blood sugar) in adults with Type 2 diabetes. It is sold under the brand name Actos, as well as Actoplus Met, Duetact, and the generic name, Pioglitazone.

Recent medical studies have linked Actos to bladder cancer. In August, 2011, the Food and Drug Administration (FDA) required the manufacturer of Actos to change its label to include a warning that patients using Actos for longer than 12 months may be at risk of developing bladder cancer. To see the FDA announcement, click here:

The FDA advises that Actos users tell their doctor right away if they have any of the following symptoms of bladder cancer: blood or red color in urine; urgent need to urinate or pain while urinating; pain in back or lower abdomen. The FDA further urges Actos users to report side effects from the use of pioglitazone medicines to the FDA MedWatch program by phone or fax, or by using their online form, available here:

If the Actos manufacturer failed to adequately research the risk of bladder cancer or warn about the potential risk and you suffered bladder cancer as a result of your Actos use, you may be entitled to compensation. Contact the experienced pharmaceutical attorneys at Schlichter, Bogard & Denton for a free consultation.

Legal Disclaimer & Privacy Policy
This web site is designed for general information only. The information presented should not be construed as legal advice and does not form the basis for an attorney/client relationship.

The choice of a lawyer is an important decision and should not be based solely on advertisements.
This web site is not intended to be advertising, and Schlichter Bogard & Denton LLP does not desire to represent anyone desiring representation based upon viewing this web site in a jurisdiction where this web site fails to comply with all laws and ethical rules of that jurisdiction. Materials on this web site may only be reproduced in their entirety (without modification) for the individual reader's personal and/or educational use and must include this notice.

We will not disclose, sell, or rent any of your identifiable personal information to any third party, unless approved by you, or required by law.